0001104659-17-041810.txt : 20170810 0001104659-17-041810.hdr.sgml : 20170810 20170627161119 ACCESSION NUMBER: 0001104659-17-041810 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AKCEA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001662524 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472608175 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 100 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 760-603-2732 MAIL ADDRESS: STREET 1: 2855 GAZELLE CT CITY: CARLSBAD STATE: CA ZIP: 92010 CORRESP 1 filename1.htm

 

Cowen and Company, LLC

599 Lexington Avenue

New York, New York 10022

 

Stifel, Nicolaus & Company, Incorporated
787 7th Avenue, 11th Floor

New York, New York 10019

 

Wells Fargo Securities, LLC
375 Park Avenue, 4th Floor
New York, New York 10019

 

June 27, 2017

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Attn:       Suzanne Hayes

 

Re:          Akcea Therapeutics, Inc.

Registration Statement on Form S-1 (File No. 333-216949)

Request for Acceleration of Effective Date

 

Ladies and Gentlemen:

 

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representatives of the several underwriters, hereby join in the request of Akcea Therapeutics, Inc. (the “Company”) for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 4:30 PM, Eastern Time, on June 29, 2017, or as soon thereafter as practicable, or at such other time as the Company or its outside counsel, Cooley LLP, request by telephone that such Registration Statement be declared effective.

 

Pursuant to Rule 460 under the Act, we, as representatives of the several underwriters, wish to advise you that we have effected the following distribution of the Company’s Preliminary Prospectus dated June 20, 2017:

 

(i)            Dates of distribution: June 20, 2017 through the date hereof

(ii)           Number of prospective underwriters to which the preliminary prospectus was furnished: 4

(iii)          Number of prospectuses furnished to investors: approximately 350

(iv)          Number of prospectuses distributed to others, including the Company, the Company’s counsel, independent accountants and underwriters’ counsel: approximately 25

 

We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have

 


 

complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 


 

 

Very truly yours,

 

 

 

COWEN AND COMPANY, LLC

 

STIFEL, NICOLAUS & COMPANY, INCORPORATED

 

WELLS FARGO SECURITIES, LLC

 

 

 

Acting severally on behalf of themselves and the

 

several Underwriters

 

 

 

 

COWEN AND COMPANY, LLC

 

 

 

 

 

 

 

By:

/s/ Tanya Joseph

 

 

Name: Tanya Joseph

 

 

Title: Managing Director

 

 

 

 

 

 

 

 

STIFEL, NICOLAUS & COMPANY,
INCORPORATED

 

 

 

 

 

 

 

By:

/s/ Seth Rubin

 

 

Name: Seth Rubin

 

 

Title: Managing Director

 

 

 

 

 

 

 

 

WELLS FARGO SECURITIES, LLC

 

 

 

 

 

 

 

By:

/s/ David Herman

 

 

Name: David Herman

 

 

Title: Director

 

[Signature Page to Underwriters’ Acceleration Request]